- Home
- STRO vs DTF Comparison
STRO vs DTF Comparison
Compare STRO & DTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- DTF
- Stock Information
- Founded
- STRO 2003
- DTF 1991
- Country
- STRO United States
- DTF United States
- Employees
- STRO N/A
- DTF N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- DTF Investment Managers
- Sector
- STRO Health Care
- DTF Finance
- Exchange
- STRO Nasdaq
- DTF Nasdaq
- Market Cap
- STRO 77.7M
- DTF 78.7M
- IPO Year
- STRO 2018
- DTF N/A
- Fundamental
- Price
- STRO $0.88
- DTF $11.19
- Analyst Decision
- STRO Hold
- DTF
- Analyst Count
- STRO 7
- DTF 0
- Target Price
- STRO $3.97
- DTF N/A
- AVG Volume (30 Days)
- STRO 513.9K
- DTF 21.1K
- Earning Date
- STRO 08-12-2025
- DTF 01-01-0001
- Dividend Yield
- STRO N/A
- DTF 3.64%
- EPS Growth
- STRO N/A
- DTF N/A
- EPS
- STRO N/A
- DTF 0.44
- Revenue
- STRO $66,434,000.00
- DTF N/A
- Revenue This Year
- STRO N/A
- DTF N/A
- Revenue Next Year
- STRO N/A
- DTF N/A
- P/E Ratio
- STRO N/A
- DTF $24.34
- Revenue Growth
- STRO N/A
- DTF N/A
- 52 Week Low
- STRO $0.52
- DTF $10.29
- 52 Week High
- STRO $5.17
- DTF $11.19
- Technical
- Relative Strength Index (RSI)
- STRO 57.66
- DTF 47.24
- Support Level
- STRO $0.83
- DTF $11.18
- Resistance Level
- STRO $1.01
- DTF $11.27
- Average True Range (ATR)
- STRO 0.07
- DTF 0.03
- MACD
- STRO 0.01
- DTF -0.00
- Stochastic Oscillator
- STRO 51.67
- DTF 10.00
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.